TREACE MEDICAL CONCEPTS, INC. (TMCI) earnings date
Mar 2, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-18
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 38 days, typically, give or take 9 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Fri, Nov 6, 2026 | before open | 37 | 8-K |
| Q2 FY2026 | Fri, Aug 7, 2026 | before open | 38 | 8-K |
| Q1 FY2026 | Fri, May 8, 2026 | before open | 38 | 8-K |
| Q4 FY2025 | Fri, Feb 27, 2026 | before open | 58 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | after close | 37 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | after close | 38 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | after close | 38 | 8-K |
| Q4 FY2024 | Thu, Feb 27, 2025 | after close | 58 | 8-K |
What they guided beta
| Q3 FY2026 | "2026 Financial Outlook The Company is updating its full-year 2026 revenue guidance to be in the range of $206 million to $210 million, from the prior range of $204 million to $212 million, representing a decline of 3% to 1% compared to full-year 2025." exhibit Read from the sentence: revenue $206 million to $210 million, FY2026 |
| Q3 FY2026 | "The Company is updating its expectation of a loss in Adjusted EBITDA to be in the range of $1.0 million to $2.0 million for full year 2026, from the prior range of $3.0 million to $5.0 million for full year 2026.* The Company reported an Adjusted EBITDA loss of $3.9 million in the full-year 2025.* The Company reiterates its expectation for a reduction in cash usage of approximately 50% for full-year 2026 as compared to the full year 2025." exhibit |
| Q3 FY2026 | "The Company’s full-year 2026 guidance assumes continued case volume growth and improving year-over-year revenue growth rates." exhibit |
| Q2 FY2026 | "2026 Financial Outlook The Company is raising its full-year 2026 revenue guidance to be in the range of $204 million to $212 million, representing a decline of 4% to 0% compared to full-year 2025." exhibit Read from the sentence: revenue $204 million to $212 million, FY2026 |
| Q2 FY2026 | "The Company is updating its expectation of a loss in Adjusted EBITDA in the range of $3.0 million to $5.0 million for full year 2026, as compared to previous guidance of a loss in the range of $4.0 million to $6.0 million." exhibit |
| Q2 FY2026 | "The Company’s full-year 2026 guidance assumes continued case volume growth and improving year-over-year growth rates for the second half of the year as headwinds are annualized." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/TMCI
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/TMCI
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/TMCI/"><img src="https://veritasdata.dev/embed/TMCI.svg" alt="TMCI earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/TMCI/)
Script
<script async src="https://veritasdata.dev/embed/TMCI.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/TMCI"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.